WELCOME TO UNICYTE

We are harnessing a unique type of stem cells to create novel classes of regenerative biotherapeutics, and deliver their benefit to patients.

Unicyte is the evolution of a fifteen year research collaboration between the Camussi lab at the University of Turin and Fresenius Medical Care AG & Co. KGaA. We have translated the ground-breaking discoveries of that collaboration into a broad pipeline based on three major technology platforms.

We are now dedicated to translating this pipeline into therapies that will improve the lives of patients with kidney or liver disease, diabetes, and cancer.

HUMAN LIVER STEM CELLS
NANO-EXTRACELLULAR VESICLES
PANCREATIC ISLETS
HUMAN LIVER STEM CELLS

HLSCs are unique adult stem cells capable not only of differentiation into multiple different cell types, but also of extensive self-renewal. They exhibit extremely high clonal stability, overcoming a major manufacturing limitation of many other stem cell sources – all while maintaining their high levels of regenerative potential in the liver and beyond.

We have received Orphan Drug Designation (from the European Medicines Agency) for HLSCs in several urea cycle disorders, and acute liver failure.

NANO-EXTRACELLULAR VESICLES

nEVs, membrane surrounded structures between 20 and 200nm in diameter are shed by many cell types, including our HLSCs. With a unique ability to transport cargo — including DNA, RNA, and proteins — between cells, nEVs play a fundamental biological role in the regulation of normal physiological processes. Following an explosion of high-profile publications on nEVs, these circulating vesicles are emerging as one of the most exciting avenues to both new therapies and diagnostics.

We have established a range of programmes based on our HLSC-nEV platform, and are moving this novel class of therapeutics towards the clinic for the safe and efficient treatment of liver & kidney disorders including transplantation, and cancer.

PANCREATIC ISLETS

We have developed a one-step process leading from HLSCs to organoids resembling natural islets (HLSC-Islets) for the application in Type 1 diabetes mellitus. Through this process, the HLSCs differentiate into multi-hormonal islet like structures with more than >50% beta-cells expressing insulin. These structures, when implanted in diabetic animals, rapidly restore a normo-glycemic profile and display near-to-normal glycemia levels under IPGTT.

Based on the very positive preclinical efficacy, we are moving the HLSC-Islets through a preclinical programme towards the clinic.